The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).
 
Adi Diab
Honoraria - Array BioPharma
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; Anaveon; AstraZeneca; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Erasca, Inc; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; MSD Oncology; Pfizer; Pierre Fabre; Replimune
 
Reham Abdel-Wahab
No Relationships to Disclose
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi; SciClone
Consulting or Advisory Role - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi; SciClone
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb (Mexico); GlaxoSmithKline; Incyte; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi; SciClone
 
Sylvie Negrier
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; MSD Oncology; Pfizer
Consulting or Advisory Role - Eisai; Ipsen; MSD Oncology
Research Funding - IPSEN (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN; MSD; Pfizer
 
Laurent Mortier
Honoraria - Bms france; MSD Oncology; Novartis; Sun pharma
Consulting or Advisory Role - BMS GmbH & Co. KG; Novartis; Sun Pharma
Research Funding - MSD Oncology (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche/Genentech; Roche/Genentech
 
Stéphane Dalle
Employment - Sanofi Pasteur (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); MSD (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pierre Fabre (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - TRIM24 regulation pending patent (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Ivana Krajsova
No Relationships to Disclose
 
Luis de la Cruz
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Incyte; MSD Oncology; Roche (Inst)
Research Funding - Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Marie Thérèse Leccia
Expert Testimony - Galderma
 
Michele Guida
Consulting or Advisory Role - Bristol Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Inflax; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Other Relationship - Avantis Medical Systems; BMS; InflaRx; Jazz Pharmaceuticals; MSD; Novartis; Pierre Fabre; Sanofi
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma; Ultimovacs
Speakers' Bureau - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; Pfizer; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Pfizer; Replimune; Replimune; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Bicara Therapeutics (Inst); Checkmate Pharmaceuticals (Inst); Idera (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Pfizer; Regeneron
 
Srinivas Chunduru
Employment - Idera
 
Shah Rahimian
Employment - Idera
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Sun Pharma
Research Funding - Novartis (Inst); Phio Pharmaceuticals (Inst)